Sökning: "chronic myeloid leukemia CML"
Visar resultat 1 - 5 av 32 avhandlingar innehållade orden chronic myeloid leukemia CML.
1. Chronic myeloid leukemia and cancer
Sammanfattning : Background Chronic myeloid leukemia (CML) is a relatively rare hematological malignancy with a constant incidence of approximately 90 new cases each year in Sweden (0.9 cases/100 000 inhabitants). The etiology is largely unknown but high doses of ionizing radiation are a known but rare risk factor. LÄS MER
2. Functional Modeling of Genes Upregulated in Chronic Myeloid Leukemia
Sammanfattning : Chronic myeloid leukemia (CML) is caused by the transformation of a primitive hematopoietic cell by the BCR/ABL1 fusion gene that is formed through the chromosomal translocation t(9;22). CML is currently successfully treated with tyrosine kinase inhibitors targeting the ABL1 kinase domain. LÄS MER
3. Targeting residual malignant cells in myeloid leukemia
Sammanfattning : Malignant cells persisting during treatment prevent cure in many patients with myeloid leukemia. In acute myeloid leukemia (AML), the failure to eradicate the leukemic clone during conventional chemotherapy is associated with leukemic relapse, mostly with dismal survival outcome. LÄS MER
4. Clinical and Experimental Studies in Chronic Myeloid Leukemia : Studies of Treatment Outcome, In Vitro Cellular Drug Resistance and Gene Expression
Sammanfattning : The aims of the studies described in the thesis were to investigate different treatment strategies in chronic myeloid leukemia (CML) patients. Furthermore, activity of imatinib was investigated by in vitro cytotoxicity assay, and the gene expression pattern in interferon treated patients. LÄS MER
5. Molecular Monitoring of Chronic Myeloid Leukemia Treated with Imatinib Mesylate
Sammanfattning : The BCR-ABL fusion gene product is a constitutively activated tyrosine kinase, which is fundamental in the pathogenesis of chronic myeloid leukemia (CML). Imatinib mesylate (imatinib, Glivec® or Gleevec®), a small molecule inhibitor of the BCR-ABL tyrosine kinase, is now the first-line treatment for all newly diagnosed chronic phase CML patients. LÄS MER